NCMW
PTGX icon

Northern Capital Management (Wisconsin)’s Protagonist Therapeutics PTGX Stock Holding History

Northern Capital Management (Wisconsin)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-16,665
Closed -$188K – 158
2017
Q2 		$188K Buy
+16,665
New +$178K 0.07% 145

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Northern Capital Management (Wisconsin)'s PTGX Position: Q3 2017 in Review

Northern Capital Management (Wisconsin) sold out of Protagonist Therapeutics (PTGX) in Q3 2017, closing a stake of 16,665 shares — an estimated $188K sold.

Northern Capital Management (Wisconsin) first reported a position in PTGX in Q2 2017 and held it in 1 quarter. The position peaked at $188K in Q2 2017. 41 funds tracked by Wall St. Rank hold PTGX as of Q3 2017.

  • Northern Capital Management (Wisconsin) reported no remaining Protagonist Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Northern Capital Management (Wisconsin) sold 16,665 Protagonist Therapeutics shares in Q3 2017, an estimated $188K.
  • Northern Capital Management (Wisconsin) first reported a position in Protagonist Therapeutics in Q2 2017 and held it in 1 quarter.
  • Northern Capital Management (Wisconsin)'s Protagonist Therapeutics position peaked at $188K in Q2 2017.
  • 41 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2017.

Based on Northern Capital Management (Wisconsin)'s 13F filing for Q3 2017, filed 27 Oct 2017.